A progressive and refractory case of breast cancer with Cowden syndrome.
Hereditary disease
Multiple hamartoma syndrome
PTEN-related cancers
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
03 Sep 2022
03 Sep 2022
Historique:
received:
18
02
2022
accepted:
02
08
2022
entrez:
3
9
2022
pubmed:
4
9
2022
medline:
8
9
2022
Statut:
epublish
Résumé
Cowden syndrome is a rare autosomal-dominant disease with a high risk of malignant tumors of the breast, commonly caused by germline mutations in the PTEN gene. Most breast cancers related to Cowden syndrome showed typically a slow-growing and favorable clinical course. Here, we report a progressive case of triple-negative breast cancer in a patient who was diagnosed with Cowden syndrome. A 35-year-old female with breast cancer was referred to our hospital. Histopathological examination of the tumor showed that it was triple-negative breast cancer with high proliferation marker. Preoperative positron emission tomography-computed tomography showed abnormal uptake in the left cerebellar hemisphere in addition to the right breast and axillary lymph node. Brain T2-weighted magnetic resonance imaging revealed hyperintense bands in the left cerebellar hemisphere lesion, which demonstrated a "tiger-stripe" appearance. The patient's mother had died of endometrial cancer. Subsequently, she underwent genetic testing, leading to a diagnosis of Cowden syndrome with a pathogenic variant c.823_840del.18 at exon 8 in PTEN. She was treated with neoadjuvant chemotherapy of eribulin and cyclophosphamide followed by adriamycin and cyclophosphamide. However, her tumors increased after these treatments. She was immediately surgically treated and received adjuvant chemotherapy of capecitabine. Unfortunately, the cancer recurred in the lung nine months after surgery. We then administered paclitaxel and bevacizumab therapy, but the disease rapidly progressed. Consequently, the patient died due to breast cancer about three months after recurrence. We report an aggressive case of cancer with Cowden syndrome which was resistant to standard chemotherapy. Alteration of the phosphatidylinositol-3 kinase/Akt/mammalian target of rapamycin pathway due to inactivating PTEN protein may be associated with chemoresistance and serves as a candidate for therapeutic intervention in PTEN-related cancers.
Sections du résumé
BACKGROUND
BACKGROUND
Cowden syndrome is a rare autosomal-dominant disease with a high risk of malignant tumors of the breast, commonly caused by germline mutations in the PTEN gene. Most breast cancers related to Cowden syndrome showed typically a slow-growing and favorable clinical course. Here, we report a progressive case of triple-negative breast cancer in a patient who was diagnosed with Cowden syndrome.
CASE PRESENTATION
METHODS
A 35-year-old female with breast cancer was referred to our hospital. Histopathological examination of the tumor showed that it was triple-negative breast cancer with high proliferation marker. Preoperative positron emission tomography-computed tomography showed abnormal uptake in the left cerebellar hemisphere in addition to the right breast and axillary lymph node. Brain T2-weighted magnetic resonance imaging revealed hyperintense bands in the left cerebellar hemisphere lesion, which demonstrated a "tiger-stripe" appearance. The patient's mother had died of endometrial cancer. Subsequently, she underwent genetic testing, leading to a diagnosis of Cowden syndrome with a pathogenic variant c.823_840del.18 at exon 8 in PTEN. She was treated with neoadjuvant chemotherapy of eribulin and cyclophosphamide followed by adriamycin and cyclophosphamide. However, her tumors increased after these treatments. She was immediately surgically treated and received adjuvant chemotherapy of capecitabine. Unfortunately, the cancer recurred in the lung nine months after surgery. We then administered paclitaxel and bevacizumab therapy, but the disease rapidly progressed. Consequently, the patient died due to breast cancer about three months after recurrence.
CONCLUSION
CONCLUSIONS
We report an aggressive case of cancer with Cowden syndrome which was resistant to standard chemotherapy. Alteration of the phosphatidylinositol-3 kinase/Akt/mammalian target of rapamycin pathway due to inactivating PTEN protein may be associated with chemoresistance and serves as a candidate for therapeutic intervention in PTEN-related cancers.
Identifiants
pubmed: 36057718
doi: 10.1186/s12957-022-02745-5
pii: 10.1186/s12957-022-02745-5
pmc: PMC9440557
doi:
Substances chimiques
Cyclophosphamide
8N3DW7272P
PTEN Phosphohydrolase
EC 3.1.3.67
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
279Informations de copyright
© 2022. The Author(s).
Références
J Clin Invest. 2019 Feb 1;129(2):452-464
pubmed: 30614812
Am J Hum Genet. 2011 Jan 7;88(1):42-56
pubmed: 21194675
Oncologist. 2013;18(10):1083-90
pubmed: 24037976
Genet Epidemiol. 2016 Jul;40(5):425-31
pubmed: 27112364
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13513-8
pubmed: 9811831
Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12479-84
pubmed: 9356475
Endocrinol Metab Clin North Am. 2017 Jun;46(2):503-517
pubmed: 28476234
J Oncol. 2020 Jul 14;2020:6384190
pubmed: 32733558
Cancer. 1992 Aug 15;70(4):869-76
pubmed: 1643619
Cancer. 2020 Mar 15;126(6):1274-1282
pubmed: 31880826
J Natl Cancer Inst. 2013 Nov 6;105(21):1607-16
pubmed: 24136893
Genet Med. 2012 Sep;14(9):819-22
pubmed: 22595938
Neurogenetics. 2018 May;19(2):77-91
pubmed: 29549527
N Engl J Med. 2017 Aug 24;377(8):791-2
pubmed: 28834474
J Med Genet. 2004 May;41(5):323-6
pubmed: 15121767
Nat Genet. 1997 May;16(1):64-7
pubmed: 9140396
Ann Intern Med. 1963 Jan;58:136-42
pubmed: 13931122
Nat Commun. 2018 Oct 4;9(1):4083
pubmed: 30287823
Oncologist. 2019 Dec;24(12):1510-e1265
pubmed: 31350329
An Bras Dermatol. 2013 Nov-Dec;88(6 Suppl 1):52-5
pubmed: 24346879
Sci Rep. 2015 Dec 11;5:17162
pubmed: 26657992
Front Endocrinol (Lausanne). 2016 Jan 11;6:188
pubmed: 26793165
Cancer Res. 1999 Nov 15;59(22):5808-14
pubmed: 10582703
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
J Genet Couns. 2009 Feb;18(1):13-27
pubmed: 18972196
J Clin Oncol. 2011 Oct 1;29(28):3747-52
pubmed: 21876083
Neurol Clin Pract. 2018 Jun;8(3):207-213
pubmed: 30105160
Cancers (Basel). 2021 Jun 22;13(13):
pubmed: 34206559
Hum Mol Genet. 1998 Mar;7(3):507-15
pubmed: 9467011
JAMA Oncol. 2017 Sep 01;3(9):1190-1196
pubmed: 28418444
Surg Case Rep. 2017 Dec;3(1):83
pubmed: 28741261
World J Surg Oncol. 2020 Aug 17;18(1):211
pubmed: 32807196
JAMA. 2007 Jun 6;297(21):2360-72
pubmed: 17545690